medic suppli devic
updat thought diabet technolog
world downgrad neutral
messag diabet defens recent market downturn med-tech
investor focus risk implant manufactur reduc elect
procedur volum agre diabet segment see less
impact concern reduc endocrinolog offic visit could slow pace
new patient add power cgm pump growth recent year
mind downgrad neutral given compani outsiz
exposur new patient driven sale prefer play within group
although pt come final remain neutral-r
due larg valuat
amid recent market volatil diabet technolog proven defens three
pure play compani segment outperform year date
vs russel med-tech investor
concern potenti elect procedur deferr neg
impact implant manufactur strap hospit budget weigh capit equip
purchas agre diabet sale like hold well current
environ worri potenti drop physician offic visit broadli due
patient compli shelter place order simpli avoid healthcar facil due
concern potenti infect ramp adopt cgm increas convers
multipl daili inject mdi patient insulin pump key growth driver
segment past year fewer visit endocrinologist
growth engin could slow near-term visibl magnitud
durat headwind still limit today risk-adjust model take
account insulin pump lower mdi convers estim
patient put flat level meanwhil assum
increment patient adopt cgm
prior estim made similar adjust intern forecast
given worsen coronaviru outbreak europ
tandem outlook highli depend new patient start step
sidelin across diabet univers calcul much
revenu estim compani deriv new patient start exercis show
particular outlier sale forecast year tie new pump
shipment meanwhil expect new patient drive sale
compani pay-as-you-go model make much instal base busi
new patient exposur low due size instal base
fact expect compani win larg share new patient
approv final also manag new patient
exposur busi model much closer durabl pump
manufactur anoth complic factor time current disrupt
even disrupt prove temporari could still cost compani valuabl time
could otherwis ramp control-iq roll-out believ new patient start
worth distinct technolog advantag
new product market unless
situat improv quickli compani could miss window capit control-
iq competit landscap heat
page analyst certif import disclosur
risk mind downgrad buy neutral
model call compani post net loss per share total
revenu cc compar prior forecast net incom
per share sale long-term continu view tandem
well-posit remain net share taker insulin pump space model
call sale grow compound-annual-growth-rate howev outlook
consensu see tabl see risk near-term number
impedi stock
elsewher expect rel insul
coronavirus-rel busi disrupt lower revenu
estim form cc revis forecast toward
bottom end manag initi guidanc growth report basi
view well-posit weather current storm believ much
defens appeal alreadi reflect stock revis ntm sale estim
current invest case much common view
compani enter strong momentum gave view time
conserv guidanc year import new product launch come
horizon keep investor excit prefer stem
slightli lower multipl ntm sale despit believ like superior
top-lin growth rate next year vs view greater upsid
potenti street estim revis forecast still consensu intrigu
long-term pipelin term product iter brand new market opportun
lower price target take account revis
estim recent peer group multipl compress reiter buy rate
page analyst certif import disclosur
tandem establish technolog leader insulin pump market
slim pump consist earn high mark patient small discret form
factor intuit user interfac beyond simpli bring consumer-ori
mindset diabet space tandem also push envelop insulin pump
technolog tandem devic updat freed patient shackl pump
could becom outdat earli lifespan compani partnership
given user access best-in-class continu glucos monitor
technolog made slim first sensor-aug pump approv let patient
make insulin dose decis without prick finger first doubl check
glucos level subsequ addit basal-iq predict low glucos suspend
featur given tandem custom ad layer protect prevent hypoglycem
excurs although believ launch tndm next-gen control-iq algorithm
leapfrog compani ahead competit think disrupt number
patient visit endocrinologist amid outbreak neg impact
tndm abil add new patient therefor miss opportun capit
control-iq launch ahead new competit product come market
long-term see tandem well posit remain net share taker
insulin pump market year come driven strong exist product portfolio
rich pipelin control-iq sport ou expans howev model call tandem
grow sale year factor step new patient start
suggest us compani may need materi lower guidanc report
may given uncertainti around tandem abil drive new patient add
move sidelin downgrad neutral
valu tandem primarili ev/sal basi use repres group small-
mid-cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim group current trade
ntm sale vs tandem multipl downgrad share buy
neutral remov pt
upsid risk rate includ better expect insulin pump adopt
despit coronaviru headwind better expect adopt control-iq drive new
patient add estim compani abil better navig current
market volatil amid global pandem achiev manag financi
downsid risk rate includ failur achiev broader adopt diabet
market highli competit rapidli evolv shift autom insulin
deliveri system potenti leav tandem depend technolog partnership
maintain competit failur achiev manag state margin
page analyst certif import disclosur
san diego ca base medic devic compani focus develop
continu glucos monitor cgm technolog aid treatment
manag diabet compani launch first cgm system st
follow recent fda approv new system sixth gener
cgm technolog last twelv year time led way
cgm grown world-wide market posit impact live
believ continu glucos monitor cgm way becom standard
care insulin-depend diabet nearli year sinc introduct
countless studi valid advantag cgm tradit point in-tim
blood glucos test reduc critic factor manag diabet
yet adopt technolog ramp slowli held back inconsist sensor accuraci
conveni qualiti life issu high increment cost therapi recent
advanc address mani histor drawback pave way rapidli
increas cgm penetr past two year
increasingli bullish long-term outlook cgm adopt
abil sustain leadership posit market best-in-class technolog coupl
improv patient access result sustain growth high end med-tech
sector model grow revenu compound-annual-growth-rate driven strong
underli market growth continu transit pharmaci channel
expans new intern market expect launch new autom
insulin deliveri technolog key technolog partner
valu primarili ev/sal basi use repres group small-
to-mid cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim current trade ntm
sale compar rang comp group lower pt
base previous multipl forward ntm sale
estim reiter buy rate
downsid risk rate includ unexpect deceler cgm market growth
recent penetr gain greater anticip adopt competit cgm
technolog increment price pressur reduc sale margin
clinic regulatori setback key pipelin program particular sensor
page analyst certif import disclosur
develop insulin infus system peopl insulin-depend diabet
compani omnipod system novel dispos patch pump believ offer
varieti advantag tradit durabl insulin pump includ elimin
tube connect pump patient improv comfort increas conveni
attribut allow carv meaning posit insulin pump
market estim top world-wide revenu last year
believ continu take share go forward driven recent transit
pharmaci roll-out dash mobil platform shift direct sale europ
late launch hybrid close loop horizon system take factor
account see posit sustain top line driven
continu execut steadi cadenc pipelin oper catalyst
repres strong fundament outlook see base case forecast
fulli reflect stock current level
valu primarili ev/sal basi use repres group small-to-
mid cap med-tech name similar growth characterist comp base
guggenheim factset consensu estim group current trade
ntm sale multipl think podd outlook warrant
premium valuat see fulli reflect stock current level remain
upsid risk rate includ faster expect insulin pump adopt within
type type diabet segment better expect adopt dash drive
new patient add estim compani abil garner better
expect price shift pharmaci channel
downsid risk rate includ failur keep pace innov
competitor caus omnipod adopt fall short street expect
disrupt compani product suppli chain faster anticip
penetr neulasta biosimilar could neg impact drug deliveri
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
revenu geographi
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd except
good sold
compani report guggenheim secur llc estim
page analyst certif import disclosur
million usd
revenu compon
compani report guggenheim secur llc estim
page analyst certif import disclosur
